123724-40-3

Upstream product

• 14633-54-6 cyclopropylphenylsulfide 

Downstream Products

• 75697-56-2 1-methoxy-1-(phenylthio)cyclopropane 
• 223689-96-1 2-(1-phenylsulfanyl-cyclopropoxy)-benzonitrile 
• 223689-98-3 3-(1-phenylsulfanyl-cyclopropoxy)-benzonitrile 
• 223689-99-4 4-(1-phenylsulfanyl-cyclopropoxy)-benzonitrile 
• 223690-12-8 2-(1-phenylsulfanyl-cyclopropoxy)-5-trifluoromethyl-pyridine 
• 223689-93-8 triisopropyl-[4-(1-phenylsulfanyl-cyclopropoxy)-phenoxy]-silane 
• 223690-06-0 1-(1-Benzenesulfonyl-cyclopropoxy)-4-chloro-benzene 
• 223690-11-7 4-(1-benzenesulfonyl-cyclopropoxy)-benzonitrile 
• 223690-10-6 3-(1-benzenesulfonyl-cyclopropoxy)-benzonitrile 
• 223690-09-3 2-(1-benzenesulfonyl-cyclopropoxy)-benzonitrile 
• 223690-07-1 4-(1-benzenesulfonyl-cyclopropoxy)-benzoic acid methyl ester 
• 223690-08-2 [4-(1-benzenesulfonyl-cyclopropoxy)-phenoxy]-triisopropyl-silane 
• 794533-58-7 2-(1-benzenesulfanyl)cyclopropyloxyethanol 
• 368834-28-0 1-Methyl-6-(1-phenylsulfanyl-cyclopropoxy)-3,4-dihydro-1H-quinolin-2-one 

Relevant academic research and scientific papers

CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER

[Object] It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C—R7; each X and Y independently show CH2, C═O, SO2, etc; Z shows CH or N; each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.; R3 shows C1-8 alkyl group; R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group; R5 and R6 show a hydrogen atom, etc.; L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)

CARBINOL DERIVATIVES HAVING CYCLIC LINKER

[Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

PRACTICAL METHOD FOR USING ALKOXIDE-ACCELERATED VINYLCYCLOBUTANE RING EXPANSIONS IN THE SYNTHESIS OF SIX-MEMBERED RINGS. UNEXPECTED ORBITAL SYMMETRY ALLOWED AND FORBIDDEN 1,3-SIGMATROPIC REARRANGEMENTS.

A practical method for utilizing the ring expansion of 2-vinylcyclobutanols to cyclohex-3-en-1-ols, even in cases in which very acid-sensitive groups are present, consists of the addition of 1-lithio- 1-methoxycyclopropanes to conjucated enals, brief trea